How can pharma support NHS transformation?
Steve How, Paul Midgley and Oli Hudson of the Wilmington Consulting Team find some answers in recently updated NHS England guidance
PharmaTimes -
June 2018
The 2018 Communications Team of the Year awards are now open for entry, so on p32 we thought we’d ask some top pharma communicators what trends and issues comms teams need to be paying attention to right now. (And given that they’re all on the CTOY steering committee, those of you thinking of entering might want to pay attention!)
Speaking of competitions, the past month has seen both of our Clinical Researcher awards revealing their winners, and we have full coverage on p36-39.
Elsewhere in the mag we take a look at the hurdles biosimilars still need to overcome to reach their full potential in the market (p30), the current state of gene therapy (p22), GSK’s financial woes (p20) and what could be the first marketed treatment for traumatic brain injury (p28).
June 2018 - magazine highlights
Is trouble on the horizon for GSK?
Ana Nicholls asks whether GSK’s revenue drop is a short-term blip or a sign of bigger problems
The ultimate cure?
Gene therapy still needs to overcome some major hurdles to truly fulfil its promise
Together as one
We caught up with IQVIA’s SVP global technology solutions, Tal Rosenberg, at the 2018 eyeforpharma Barcelona conference as the company announced the EU launch of its Orchestrated Customer Engagement product, which aims to harmonise pharma's interaction with customers
Company focus: Vasopharm
CEO Christian Wandersee explains the hurdles and hopes when developing drugs for traumatic brain injury, a devastating condition for which there is no existing drug treatment
The biosimilars era
Biosimilars may have proven their worth, but how can adoption be sped up?
On the comms radar
Pharma comms is one of the most dynamic sectors of the industry. So, what should be on communicators’ radar?
Patient Files: Familial Chylomicronaemia Syndrome
Dr Karishma Patel talks to PharmaTimes about the challenges of life with this ultra-rare genetic disorder
